Close Menu

NEW YORK (GenomeWeb) – Rosetta Genomics said today that it has priced a public offering of 1.9 million securities units at $1.40 each for gross proceeds of roughly $2.7 million.

The units consist of one ordinary share and a warrant to purchase half an ordinary share. The warrants to purchase an aggregate of 974,987 ordinary shares have an exercise price of $1.50 per ordinary share. The warrants will become exercisable immediately upon issuance and expire in five years.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jun
13

Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type. 

Jun
18
Sponsored by
ArcherDX

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect. 

Jun
19

This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.